浏览全部资源
扫码关注微信
网络首发:2016-10-14,
纸质出版:2016
移动端阅览
亚甲基四氢叶酸还原酶基因多态性和结直肠癌对FOLFOX6方案化疗反应的相关性[J]. 中山大学学报(医学科学版), 2016,37(5).
Relationship between MTHFR Polymorphism and Chemotherapy Reactivity to FOLFOX6 Regimen of Colorectal Cancer Patients[J]. Journal of Sun Yat-sen University (Medical Sciences), 2016, 37(5).
亚甲基四氢叶酸还原酶基因多态性和结直肠癌对FOLFOX6方案化疗反应的相关性[J]. 中山大学学报(医学科学版), 2016,37(5). DOI:
Relationship between MTHFR Polymorphism and Chemotherapy Reactivity to FOLFOX6 Regimen of Colorectal Cancer Patients[J]. Journal of Sun Yat-sen University (Medical Sciences), 2016, 37(5). DOI:
【目的】 分析结直肠癌患者亚甲基四氢叶酸还原酶(MTHFR)基因C677T多态性与FOLFOX6方案化疗疗效和毒性的相关性。【方法】 收集经病理学确诊的III-IV期结直肠腺癌患者92例。所有患者均接受FOLFOX6方案化疗,化疗前抽取患者外周血,提取DNA,采用DNA测序的方法检测MTHFR基因C677T多态性,并分析其与化疗方案疗效及毒性的相关性。【结果】 92例结直肠癌患者中,MTHFR C677T CC、CT、TT基因型频率分别为:55.4%、40.2%、4.3%。携带T基因型的患者疾病控制率高于CC型患者(P = 0.054)。在血液毒性中,C/C基因型患者中性粒细胞减少发生率较C/T、T/T基因型低,差异具有显著性(P < 0.05)。其他血液学毒性及非血液学毒性的发生率同MTHFRC677T多态性无相关性。【结论】MTHFR C677T基因多态性,可作为结直肠癌患者化疗的疾病控制率和粒细胞减少的预测指标。
【Objective】 To investigate the relationship between Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and chemotherapy reactivity of colorectal cancer patients treated by FOLFOX6 regimen. 【Methods】 92 stage Ⅲ and Ⅳ colorectal carcinoma patients confirmed by pathology were treated with FOLFOX6 regimen. DNA of peripheral blood was obtained before chemotherapy. MTHFR genotypes were detected by PCR and sequencing method. The relationship between C677T genotypes and response rate as well as toxicities were analyzed. 【Results】 Of the total 92 patients, genotype frequency of MTHFR C677T C/C, C/T, and T/T were 55.4%, 40.2%, and 4.3%, respectively. Patients with CT or TT genotype showed better disease control rate (DCR) of chemotherapy than the patients with CC genotype(P = 0.054). Compared with patients with C/T and T/T genotype, patients of C/C genotype were correlated with decreased rate of neutropenia to chemotherapy(P < 0.05). No significant differences were observed concerning other hematologic toxicities and non -hematologic toxicities. 【Conclusion】 The present study indicates that polymorphism of MTHFR C677T may be a factor to predict the DCR and neutropenia of colorectal cancer patients treated by FOLFOX6 regimen.
0
浏览量
396
下载量
CSCD
关联资源
相关文章
相关作者
相关机构